2.50
Hdl Handle:
http://hdl.handle.net/10541/78905
Title:
Pegvisomant in the treatment of acromegaly.
Authors:
Parkinson, Craig; Scarlett, J A; Trainer, Peter J
Abstract:
Epidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date.
Affiliation:
Department of Endocrinology, Christie Hosptial, Wilmslow Road, Manchester M20 4BX, UK.
Citation:
Pegvisomant in the treatment of acromegaly. 2003, 55 (10):1303-14 Adv. Drug Deliv. Rev.
Journal:
Advanced Drug Delivery Reviews
Issue Date:
26-Sep-2003
URI:
http://hdl.handle.net/10541/78905
DOI:
10.1016/S0169-409X(03)00111-X
PubMed ID:
14499709
Type:
Article
Language:
en
ISSN:
0169-409X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorParkinson, Craig-
dc.contributor.authorScarlett, J A-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-08-27T14:18:41Z-
dc.date.available2009-08-27T14:18:41Z-
dc.date.issued2003-09-26-
dc.identifier.citationPegvisomant in the treatment of acromegaly. 2003, 55 (10):1303-14 Adv. Drug Deliv. Rev.en
dc.identifier.issn0169-409X-
dc.identifier.pmid14499709-
dc.identifier.doi10.1016/S0169-409X(03)00111-X-
dc.identifier.urihttp://hdl.handle.net/10541/78905-
dc.description.abstractEpidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date.en
dc.language.isoenen
dc.subject.meshAcromegaly-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshReceptors, Somatotropin-
dc.titlePegvisomant in the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hosptial, Wilmslow Road, Manchester M20 4BX, UK.en
dc.identifier.journalAdvanced Drug Delivery Reviewsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.